Aldeyra Therapeutics

LEXINGTON, MA · Biotech · Public

Small-molecule therapeutics targeting immune-mediated diseases

Claim this profile

Follows are private to you and power your alerts

Updated · aldeyra.com

Sector
Biotech
Headquarters
LEXINGTON, MA
Latest Form D
$10M, Feb 2019
Total capital
$24.6M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$24.6M
4 Form D · last Feb 2019
92 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
20
20 pending · first 2021
Rank in peer group#47 of 1449

Capital timeline

2013201420152016201720182019FEDERAL ↑EQUITY ↓Cumulative $24.6M1st Form D$4.8M2nd Form D$7.8M4th Form D$10M
2013201520172019FEDERAL ↑EQUITY ↓Cumulative $24.6M1st Form D$4.8M2nd Form D$7.8M4th Form D$10M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$10M
  • Private capital raisedForm D · SEC · 3rd filing$2M
  • Private capital raisedForm D · SEC · 2nd filing$7.8M
  • Private capital raisedForm D · SEC · 1st filing$4.8M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#47 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Todd C. BradyResearcherExecutive Officer, DirectorLinked by 3 patents
  • Ben J. BronsteinDirectorNamed in SEC Form D filings
  • C. Boyd L. ClarkeDirectorNamed in SEC Form D filings
  • C.Boyd C. ClarkeDirectorNamed in SEC Form D filings
  • David L. ClarkExecutive OfficerNamed in SEC Form D filings
  • David L. McMullinExecutive OfficerNamed in SEC Form D filings
Show all 15 people
  • Gary J. PhillipsDirectorNamed in SEC Form D filings
  • Jesse I. TreuDirectorNamed in SEC Form D filings
  • Joshua ReedExecutive OfficerNamed in SEC Form D filings
  • Martin J. JoyceDirectorNamed in SEC Form D filings
  • Neal J. WalkerDirectorNamed in SEC Form D filings
  • Richard I. DouglasDirectorNamed in SEC Form D filings
  • Scott C. YoungExecutive OfficerNamed in SEC Form D filings
  • Stephen I. MachathaExecutive OfficerNamed in SEC Form D filings
  • Stephen C. TulipanoExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 20 granted of 40
  • PendingOphthalmic Formulations Of MethotrexateUSPTOApplication 19643612
  • GrantedOphthalmic Formulations Of MethotrexateUSPTOUS 12,616,699
  • PendingMethods Of Treating Sjögren-larssen SyndromeUSPTOApplication 18850826
Show all 40 patent records

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .